The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma: the experience of the Istituto Tumori of Milan.
CEA determination has attained an important role in the clinical management of patients with tumors of the colorectal tract. In this paper the experience of the Istituto Tumori of Milan is reviewed and the results are discussed. Three hundred and thirty-six patients were followed after curative resection of colorectal carcinoma. The follow-up period was 15 years, from January 1975 to December 1990 (global follow-up 1358 years). In the course of follow-up 136 patients developed recurrent disease. The number of CEA determinations for each patient ranged from 1 to 37 (mean 8, total 3330). CEA levels of presurgical patients were related to the clinical stage. Among patients who developed recurrences 61% showed an increase in CEA serum levels. In 200 patients with a negative follow-up we observed only 15 cases of false-positive results.
Seregni
E
E
Nuclear Medicine Division, Istituto Nazionale Tumori, Milano, Italy.
Bombardieri
E
E
Bogni
A
A
Crippa
F
F
De Jager
E
E
Buraggi
G L
GL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000276:immunology; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000276:immunology; D011379:Prognosis; D012189:Retrospective Studies
D002272:Carcinoembryonic Antigen